Investigational drug · Phase 2
DD01
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NAFLD, NASH.
Phase 2Last checked: Nov 19, 2026Latest source record: May 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "DD01"
First trial start
2024
Jun 13, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DD01", any sponsor or status.
Conditions studied
As listed on its trial records.
- NAFLD
- NASH
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DD01" as an intervention, largest first.
- A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLDPivotal-lookingCompleted
Neuraly, Inc.Industry
NCT04812262 · 255 participants · Start Feb 24, 2021 · Primary completion Dec 20, 2022
Drug: DD01; Placebo · For: Overweight and Obesity; Type2 Diabetes; NAFLD
Sites: Chula Vista, California; Fort Myers, Florida; Orlando, Florida · 4 sites in all
Neuraly, Inc.Industry
NCT06410924 · 67 participants · Start Jun 13, 2024 · Primary completion May 20, 2025
Drug: DD01; Placebo · For: NAFLD; NASH
Sites: Maitland, Florida; Monroe, Louisiana; West Monroe, Louisiana · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The glucagon and GLP-1 receptor dual agonist DD01 for metabolic dysfunction-associated steatotic liver disease and steatohepatitis (DD01-DN-02): 12-week results from a randomised, double-blind, multicentre, placebo-controlled, phase 2 trial.
Noureddin M, Dunn W, Patil R, et al. · Lancet Gastroenterol Hepatol 2026
- Corrigendum to: Modern-Day Therapeutics and Ongoing Clinical Trials against Type 2 Diabetes Mellitus: A Narrative Review.
Tiwari RK, Ahmad A, Chadha M, et al. · Curr Diabetes Rev 2026
- Top-Line Phase 2 Results of DD01, a Dual GLP-1/Glucagon Agonist, Lead to Rapid Improvements in Liver and Metabolic Endpoints in Patients With MASLD/MASH.
· Gastroenterol Hepatol (N Y) 2025
- Impaired Myocardial Sympathetic Innervation Is Associated with Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction: 11C-Hydroxyephedrine PET Study.
Aikawa T, Naya M, Obara M, et al. · J Nucl Med 2017
- Tolterodine does not affect memory assessed by passive-avoidance response test in mice.
Cappon GD, Bush B, Newgreen D, et al. · Eur J Pharmacol 2008
- Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats.
Modiri AR, Alberts P, Gillberg PG · Urology 2002
Also in development for NAFLD
- EfinopegdutideMK-6024, HM12525APhase 22 trials
Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.